Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

RANKL/RANK control Brca1 mutation- .

Sigl V, Owusu-Boaitey K, Joshi PA, Kavirayani A, Wirnsberger G, Novatchkova M, Kozieradzki I, Schramek D, Edokobi N, Hersl J, Sampson A, Odai-Afotey A, Lazaro C, Gonzalez-Suarez E, Pujana MA, Cimba F, Heyn H, Vidal E, Cruickshank J, Berman H, Sarao R, Ticevic M, Uribesalgo I, Tortola L, Rao S, Tan Y, Pfeiler G, Lee EY, Bago-Horvath Z, Kenner L, Popper H, Singer C, Khokha R, Jones LP, Penninger JM.

Cell Res. 2016 Jul;26(7):761-74. doi: 10.1038/cr.2016.69. Epub 2016 May 31.

2.

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, Lok SW, Mann GB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Rohrbach K, Huang LY, Soriano R, Smyth GK, Dougall WC, Visvader JE, Lindeman GJ.

Nat Med. 2016 Aug;22(8):933-9. doi: 10.1038/nm.4118. Epub 2016 Jun 20.

PMID:
27322743
3.

RANKL and RANK: From Mammalian Physiology to Cancer Treatment.

Rao S, Cronin SJF, Sigl V, Penninger JM.

Trends Cell Biol. 2018 Mar;28(3):213-223. doi: 10.1016/j.tcb.2017.11.001. Epub 2017 Dec 11. Review.

PMID:
29241686
4.

RANKL/RANK: from bone loss to the prevention of breast cancer.

Sigl V, Jones LP, Penninger JM.

Open Biol. 2016 Nov;6(11). pii: 160230. Review.

5.

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.

Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC.

Nature. 2010 Nov 4;468(7320):103-7. doi: 10.1038/nature09495. Epub 2010 Sep 29.

PMID:
20881963
6.

Can we prevent BRCA1-associated breast cancer by RANKL inhibition?

Kotsopoulos J, Singer C, Narod SA.

Breast Cancer Res Treat. 2017 Jan;161(1):11-16. doi: 10.1007/s10549-016-4029-z. Epub 2016 Oct 25. Review.

PMID:
27783278
7.

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM.

Nature. 2010 Nov 4;468(7320):98-102. doi: 10.1038/nature09387. Epub 2010 Sep 29.

8.

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Cuyàs E, Corominas-Faja B, Martín MM, Martin-Castillo B, Lupu R, Brunet J, Bosch-Barrera J, Menendez JA.

Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.

9.

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.

Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M.

Nature. 2011 Feb 24;470(7335):548-53. doi: 10.1038/nature09707. Epub 2011 Feb 16.

10.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.

Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A.

J Exp Clin Cancer Res. 2019 Jan 8;38(1):12. doi: 10.1186/s13046-018-1001-2. Review.

11.

RANKL inhibition: a promising novel strategy for breast cancer treatment.

González-Suárez E.

Clin Transl Oncol. 2011 Apr;13(4):222-8. doi: 10.1007/s12094-011-0646-5. Review.

PMID:
21493182
13.

c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer.

Regan JL, Kendrick H, Magnay FA, Vafaizadeh V, Groner B, Smalley MJ.

Oncogene. 2012 Feb 16;31(7):869-83. doi: 10.1038/onc.2011.289. Epub 2011 Jul 18.

PMID:
21765473
14.

NF-κB at the Crossroads of Normal Mammary Gland Biology and the Pathogenesis and Prevention of BRCA1-Mutated Breast Cancer.

Sau A, Cabrita MA, Pratt MAC.

Cancer Prev Res (Phila). 2018 Feb;11(2):69-80. doi: 10.1158/1940-6207.CAPR-17-0225. Epub 2017 Nov 3. Review.

15.

Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.

Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM.

Oncotarget. 2017 Jan 17;8(3):3811-3825. doi: 10.18632/oncotarget.14013.

16.

Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.

Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, Fineman L, Chen X, Culhane AC, Cai H, Rodig SJ, Bronson RT, Jonkers J, Nussenzweig A, Kanellopoulou C, Livingston DM.

Proc Natl Acad Sci U S A. 2013 May 21;110(21):8632-7. doi: 10.1073/pnas.1305362110. Epub 2013 May 8.

17.

Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.

Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, Fernández-Ramires R, Costes SV, Guinó E, Chen H, Evans GJ, Mohan P, Català I, Petit A, Aguilar H, Villanueva A, Aytes A, Serra-Musach J, Rennert G, Lejbkowicz F, Peterlongo P, Manoukian S, Peissel B, Ripamonti CB, Bonanni B, Viel A, Allavena A, Bernard L, Radice P, Friedman E, Kaufman B, Laitman Y, Dubrovsky M, Milgrom R, Jakubowska A, Cybulski C, Gorski B, Jaworska K, Durda K, Sukiennicki G, Lubiński J, Shugart YY, Domchek SM, Letrero R, Weber BL, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, Roozendaal CE; HEBON; EMBRACE, Easton DF, Peock S, Cook M, Oliver C, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Eccles D, Douglas F, Brewer C, Nevanlinna H, Heikkinen T, Couch FJ, Lindor NM, Wang X, Godwin AK, Caligo MA, Lombardi G, Loman N, Karlsson P, Ehrencrona H, Wachenfeldt Av; SWE-BRCA, Barkardottir RB, Hamann U, Rashid MU, Lasa A, Caldés T, Andrés R, Schmitt M, Assmann V, Stevens K, Offit K, Curado J, Tilgner H, Guigó R, Aiza G, Brunet J, Castellsagué J, Martrat G, Urruticoechea A, Blanco I, Tihomirova L, Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB; BCFR, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Deissler H, Varon-Mateeva R, Sutter C, Niederacher D, Imyamitov E, Sinilnikova OM, Stoppa-Lyonne D, Mazoyer S, Verny-Pierre C, Castera L, de Pauw A, Bignon YJ, Uhrhammer N, Peyrat JP, Vennin P, Fert Ferrer S, Collonge-Rame MA, Mortemousque I; GEMO Study Collaborators, Spurdle AB, Beesley J, Chen X, Healey S; kConFab, Barcellos-Hoff MH, Vidal M, Gruber SB, Lázaro C, Capellá G, McGuffog L, Nathanson KL, Antoniou AC, Chenevix-Trench G, Fleisch MC, Moreno V, Pujana MA.

PLoS Biol. 2011 Nov;9(11):e1001199. doi: 10.1371/journal.pbio.1001199. Epub 2011 Nov 15.

18.

Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.

Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL; kConFab Investigators.

Genes Chromosomes Cancer. 2004 Mar;39(3):236-48.

PMID:
14732925
19.

The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.

Moynahan ME.

Oncogene. 2002 Dec 16;21(58):8994-9007. Review.

20.

Evidence for a link between TNFRSF11A and risk of breast cancer.

Bonifaci N, Palafox M, Pellegrini P, Osorio A, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Mariette F, Bernard L, Radice P, Kaufman B, Laitman Y, Milgrom R, Friedman E, Sáez ME, Climent F, Soler MT, Diez O, Balmaña J, Lasa A, Ramón y Cajal T, Miramar MD, de la Hoya M, Pérez-Segura P, Caldés T, Moreno V, Urruticoechea A, Brunet J, Lázaro C, Blanco I, Pujana MA, González-Suárez E.

Breast Cancer Res Treat. 2011 Oct;129(3):947-54. doi: 10.1007/s10549-011-1546-7. Epub 2011 May 4.

PMID:
21541702

Supplemental Content

Support Center